SCHEMBL8521535

SCHEMBL8521535

COC(=O)c1c(Cl)cc(Cl)nc1/N=C\NO

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.39
▸ ALDH1A1 P00352 3/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ CYP2C9 P11712 4/20 0.33
▸ CYP2D6 P10635 2/20 0.33
▸ PLA2G2A P14555 2/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ HTT P42858 2/20 0.32
▸ HPGD P15428 1/20 0.32
▸ CASP1 P29466 1/20 0.32
▸ HSD17B10 Q99714 1/20 0.32
▸ NQO2 P16083 1/20 0.32
▸ LMNA P02545 1/20 0.32
▸ GAA P10253 1/20 0.32
▸ TSHR P16473 1/20 0.32
▸ CYP4Z1 Q86W10 1/20 0.32
▸ KMT2A Q03164 2/20 0.32
▸ NR4A2 P43354 1/20 0.32
▸ F2 P00734 1/20 0.32
▸ POLB P06746 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1710208 0.77 KDM4E (0.44) KDM4EALDH1A1SMN1; SMN2CYP3A4HPGD
SCHEMBL12380495 0.74 KDM4E (0.44) KDM4EALDH1A1SMN1; SMN2PLA2G2ACYP3A4
SCHEMBL21403273 0.72 KDM4E (0.36) KDM4EALDH1A1SMN1; SMN2PLA2G2AHPGD
SCHEMBL29886117 0.72 KDM4E (0.36) KDM4EALDH1A1SMN1; SMN2PLA2G2AHPGD
SCHEMBL21403274 0.72 KDM4E (0.36) KDM4EALDH1A1SMN1; SMN2PLA2G2AHPGD
SCHEMBL17054798 0.72 KDM4E (0.40) KDM4EALDH1A1SMN1; SMN2PLA2G2ACYP3A4
SCHEMBL24070302 0.71 KDM4E (0.42) KDM4EALDH1A1SMN1; SMN2PLA2G2ACYP3A4
SCHEMBL145259 0.71 NQO2 (0.44) KDM4EALDH1A1SMN1; SMN2HPGDNQO2
SCHEMBL29364806 0.71 NQO2 (0.44) KDM4EALDH1A1SMN1; SMN2HPGDNQO2
SCHEMBL17054799 0.68 KDM4E (0.42) KDM4EALDH1A1SMN1; SMN2CYP3A4HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200339563-A1 METHOD FOR PRODUCING TRIAZOLOPYRIDINE COMPOUND SHIONOGI & CO., LTD. (JP) 2020-10-29 — — US disclosed
US-20160145254-A1 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT JAPAN TOBACCO INC. (JP) 2016-05-26 — — US disclosed
EP-2455381-B9 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR AND ERYTHROPOIETIN PRODUCTION INDUCER JAPAN TOBACCO INC (JP) 2014-10-22 — — EP disclosed
EP-2455381-B1 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR AND ERYTHROPOIETIN PRODUCTION INDUCER JAPAN TOBACCO INC (JP) 2014-05-28 — — EP disclosed
US-20130096155-A1 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT JAPAN TOBACCO INC. (JP) 2013-04-18 — — US disclosed
US-8283465-B2 Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor or erythropoietin production-inducing agent JAPAN TOBACCO INC. (JP) 2012-10-09 — — US disclosed
EP-2455381-A1 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR AND ERYTHROPOIETIN PRODUCTION INDUCER Japan Tobacco, Inc. (JP) 2012-05-23 — — EP disclosed
US-20110077267-A1 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT JAPAN TOBACCO INC. (JP) 2011-03-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200339563-A1 METHOD FOR PRODUCING TRIAZOLOPYRIDINE COMPOUND EPOR, PAH, THPO KDM4E 482/4885ALDH1A1 233/4885SMN1; SMN2 2154/4885
US-20130096155-A1 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT EGLN3, EPOR, EGLN2 KDM4E 931/4885ALDH1A1 309/4885SMN1; SMN2 2585/4885
US-20110077267-A1 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT EGLN3, EPOR, EGLN2 KDM4E 931/4885ALDH1A1 309/4885SMN1; SMN2 2585/4885
US-20160145254-A1 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT EGLN3, EPOR, EGLN2 KDM4E 931/4885ALDH1A1 309/4885SMN1; SMN2 2585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback